L Etienne

Summary

Country: France

Publications

  1. ncbi Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients
    Torsten Bohler
    Department of Internal Medicine Nephrology, Charite Campus Mitte, Humboldt University, Berlin, Germany
    Int Immunopharmacol 7:88-95. 2007
  2. ncbi Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans
    Torsten Bohler
    INSERM U466, Institut Louis Bugnard, Toulouse, France
    Ther Drug Monit 29:77-86. 2007
  3. ncbi Effect of FTY720 on apoptosis of smooth muscle cells
    T Bohler
    INSERM U858, CHU Rangueil, 31403 Toulouse, France
    Transplant Proc 39:2624-6. 2007
  4. ncbi Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferation
    Torsten Bohler
    INSERM U858, Institute Louis Bugnard, CHU Rangueil, Toulouse, France
    Transpl Immunol 18:319-23. 2008
  5. ncbi Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients
    Torsten Bohler
    INSERM U858, Equipe 10, IFR 31, Institut Louis Bugnard, Batiment L3, CHU Rangueil, France
    Int Immunopharmacol 8:769-73. 2008
  6. ncbi Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients
    Torsten Bohler
    INSERM U858, I2MR, Eq 10, Institut Louis Bugnard, Batiment L3, CHU Rangueil, 1 avenue J Poulhes, 31403 Toulouse Cedex 4, France
    Cytokine 42:306-11. 2008
  7. ncbi Cytokines correlate with age in healthy volunteers, dialysis patients and kidney-transplant patients
    Torsten Bohler
    INSERM U 858 EQ 10, Institut Louis Bugnard, 1 Ave J Poulhès, CHU Rangueil, 3100 Toulouse, France
    Cytokine 45:169-73. 2009
  8. ncbi FTY720 Inhibits Tumor Necrosis Factor-alpha-Induced Proliferation and Extracellular Signal-Regulated Kinase Phosphorylation of Human Smooth Muscle Cells
    T Bohler
    INSERM U858 I2MR EQ 10 Artériosclérose et Artériosclérose de Greffe, CHU Rangueil, Toulouse, France
    Transplant Proc 41:705-6. 2009

Detail Information

Publications8

  1. ncbi Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients
    Torsten Bohler
    Department of Internal Medicine Nephrology, Charite Campus Mitte, Humboldt University, Berlin, Germany
    Int Immunopharmacol 7:88-95. 2007
    ..In conclusion FTY720 treatment reduces B-cells expressing CD62L to a significant lesser degree than T-cells expressing CD62L...
  2. ncbi Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans
    Torsten Bohler
    INSERM U466, Institut Louis Bugnard, Toulouse, France
    Ther Drug Monit 29:77-86. 2007
    ..We conclude that these biomarkers used in whole-blood assays are suitable for PD of immune modulators in clinical trials...
  3. ncbi Effect of FTY720 on apoptosis of smooth muscle cells
    T Bohler
    INSERM U858, CHU Rangueil, 31403 Toulouse, France
    Transplant Proc 39:2624-6. 2007
    ..Hyperproliferation of smooth muscle cells (SMCs) plays a key role in allograft arteriosclerosis. This prompted us to investigate the effect of the novel immune modulator and synthetic sphingolipid FTY720 on apoptosis of SMCs...
  4. ncbi Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferation
    Torsten Bohler
    INSERM U858, Institute Louis Bugnard, CHU Rangueil, Toulouse, France
    Transpl Immunol 18:319-23. 2008
    ..Further experiments showed that the immune inhibitory effects by Tabebuia were not mediated by its pharmacological lead compound beta-lapachone and only observed in aqueous but not in ethanol plant extracts...
  5. ncbi Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients
    Torsten Bohler
    INSERM U858, Equipe 10, IFR 31, Institut Louis Bugnard, Batiment L3, CHU Rangueil, France
    Int Immunopharmacol 8:769-73. 2008
    ....
  6. ncbi Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients
    Torsten Bohler
    INSERM U858, I2MR, Eq 10, Institut Louis Bugnard, Batiment L3, CHU Rangueil, 1 avenue J Poulhes, 31403 Toulouse Cedex 4, France
    Cytokine 42:306-11. 2008
    ..In vitro, everolimus inhibited lymphocyte proliferation and IL-10 synthesis dose dependently in anti-CD3 mAb and LPS stimulated peripheral blood mononuclear cell cultures derived from human volunteers...
  7. ncbi Cytokines correlate with age in healthy volunteers, dialysis patients and kidney-transplant patients
    Torsten Bohler
    INSERM U 858 EQ 10, Institut Louis Bugnard, 1 Ave J Poulhès, CHU Rangueil, 3100 Toulouse, France
    Cytokine 45:169-73. 2009
    ....
  8. ncbi FTY720 Inhibits Tumor Necrosis Factor-alpha-Induced Proliferation and Extracellular Signal-Regulated Kinase Phosphorylation of Human Smooth Muscle Cells
    T Bohler
    INSERM U858 I2MR EQ 10 Artériosclérose et Artériosclérose de Greffe, CHU Rangueil, Toulouse, France
    Transplant Proc 41:705-6. 2009
    ..We concluded that FTY720 may be a useful drug to inhibit chronic vascular rejection...